Using advanced imaging to improve surgery for skin cancer
Official title: Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
Run by University of Rochester · NCT06473103 · Data updated 2026-11-12
This study is testing a new imaging technique to see if it can help doctors remove all of the skin cancer during surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 52 (estimated) |
| Sponsor | University of Rochester Academic / other |
| Locations | 1 site (Victor, New York) |
| Status | Recruiting |
| Started | October 29, 2024 |
| Main results expected | March 2026 |
| Study ends | April 2026 |
| Registry record updated | March 17, 2025 |
| Trial ID | NCT06473103 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients undergoing treatment for basal cell carcinoma who are not receiving Mohs surgery.
✕Probably not a fit
Patients who are not undergoing surgical treatment for basal cell carcinoma or those receiving Mohs surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of two photon fluorescence microscopy (TPFM) in detecting residual basal cell carcinoma during standard local excision procedures. The study will involve fluorescently labeling excised tissue and measuring the distance to inked surgical margins using TPFM, followed by standard permanent section evaluations for confirmation. By comparing the results from TPFM with traditional methods, the study seeks to enhance surgical outcomes and ensure complete removal of cancerous tissue.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate surgical margins and better outcomes for patients with basal cell carcinoma.
How similar studies have gone: While the use of advanced imaging techniques in surgical oncology is gaining traction, this specific application of TPFM for basal cell carcinoma is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Undergoing treatment for basal cell carcinoma without Mohs surgery at the performance site * Able to read and understand consent form Exclusion Criteria: * None
Where it's running
-
Rochester Dermatologic Surgery
Victor, New York, United States Recruiting
Study contacts
- Principal investigator: Michael Giacomelli — University of Rochester
- Study coordinator: Michael Giacomelli, Ph.D.
- Email: mgiacome@ur.rochester.edu
- Phone: 5852766260
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based risk and subtype prediction for basal cell carcinoma using dermoscopic images
A retrospective study tests an artificial intelligence model to classify basal cell carcinoma as low- or high-risk and to predict histopathological subtypes from archived dermoscopic images.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
Vitamin D and light therapy to boost skin cancer response before surgery
This study tests whether giving Vitamin D or a placebo around the time of a light-based treatment (PDT) can help boost skin cancer treatment before Mohs surgery or ED&C in adults with basal cell or squamous cell carcinoma.
-
Using line-field confocal OCT to map Mohs surgery margins for basal cell carcinoma
This tests whether line-field confocal optical coherence tomography (LC-OCT) can noninvasively show the edges of basal cell carcinomas in adults scheduled for Mohs surgery.
-
Neoadjuvant Opdualag (nivolumab + relatlimab) versus nivolumab for resectable high-risk basal cell carcinoma
This trial tests whether adding relatlimab to nivolumab before surgery helps people with resectable high‑risk basal cell carcinoma shrink tumors and improve surgical outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.